DUB to the rescue

Wei Pin Teh; He Zhu; Jarrod A Marto; Sara J Buhrlage

doi:10.1016/j.molcel.2022.03.039

DUB to the rescue

Mol Cell. 2022 Apr 21;82(8):1411-1413. doi: 10.1016/j.molcel.2022.03.039.

Authors

Wei Pin Teh¹, He Zhu², Jarrod A Marto², Sara J Buhrlage³

Affiliations

¹ Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
² Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA.
³ Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA. Electronic address: saraj_buhrlage@dfci.harvard.edu.

PMID: 35452613
DOI: 10.1016/j.molcel.2022.03.039

Abstract

Henning et al. (2022) report development of a novel class of agents, bivalent deubiquitinase (DUB)-targeting chimeras (DUBTACs), that can selectively stabilize protein targets. These findings encourage further pursuit of targeted protein stabilization as a new paradigm in chemical biology and drug discovery.

Publication types

Comment

MeSH terms

Deubiquitinating Enzymes* / metabolism
Drug Discovery*

Substances

Deubiquitinating Enzymes